Kathryn Ratanavanich, DO
Nephrology · Washington, DCNPI 1801093919
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.6% of the total across 96 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $640 and has fallen 58.7% since, to $264 in 2025.
Across 96 payments — averaging $23.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$380
- AstraZeneca$234
- OPKO Pharmaceuticals, LLC$204
- Akebia Therapeutics Inc$145
- Amgen$139
- Calliditas Therapeutics US Inc.$124
- plus $1K from 15 others
What the payments were for
- Food & beverage$2,05691%
- Education$2139%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 17 | $380 |
| AstraZeneca(2 entities) | 10 | $234 |
| OPKO Pharmaceuticals, LLC | 8 | $204 |
| Akebia Therapeutics Inc | 6 | $145 |
| Amgen | 6 | $139 |
| Calliditas Therapeutics US Inc. | 6 | $124 |
| Novartis | 5 | $116 |
| Ardelyx, Inc. | 5 | $112 |
| Bayer | 5 | $110 |
| Otsuka America Pharmaceutical, Inc. | 5 | $109 |
| Fresenius USA Marketing, Inc. | 5 | $94 |
| Travere Therapeutics, Inc. | 4 | $86 |
| Baxter Healthcare | 1 | $77 |
| Aurinia Pharma U.S., Inc. | 3 | $76 |
| Boehringer Ingelheim | 3 | $75 |
| Mallinckrodt Enterprises LLC | 2 | $62 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| Scpharmaceuticals Inc. | 1 | $25 |
| GSK | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
How this compares
$2,269 in reported general payments places this provider in the 70th percentile of 62 nephrology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 15 | $23,602 |
| RayaldeeCalcifediol | 13 | $15,867 |
| LokelmaSodium Zirconium Cyclosilicate | 21 | $14,838 |
| Sevelamer Carbonate | 20 | $7,040 |
| Potassium Citrate ErPotassium Citrate | 19 | $1,818 |
| Calcium Acetate | 11 | $899 |
| Clonidine | 11 | $812 |
| Hydralazine Hcl | 51 | $596 |
| Furosemide | 100 | $423 |
| Allopurinol | 38 | $347 |
| Amlodipine Besylate | 68 | $294 |
| Labetalol Hcl | 17 | $260 |
| Carvedilol | 17 | $166 |
| Losartan Potassium | 15 | $106 |
| Clonidine Hcl | 13 | $84 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $94 | $23,60215 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $204 | $15,86713 claims |
| AstraZenecaLokelma | $234 | $14,83821 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 62 nephrology providers in District of Columbia.
Other nephrology in Washington
- Ashte CollinsWashington$1M
- Bruce LeslieWashington$217K
- Janani RangaswamiWashington$152K
- Robert RubinWashington$119K
- Ehsan Nobakht HaghighiWashington$50K
- Christopher WilcoxWashington$41K
- Michael LipkowitzWashington$21K
- Dominic RajWashington$19K
- Cosette JamiesonWashington$13K
- Elwin BustosWashington$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.